TrialsgrambetaRCTs are beautiful

FIDELIO-DKD

2020

Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease

In 5,734 patients with type 2 diabetes and CKD, finerenone reduced the composite of kidney failure, ≥40% eGFR decline or renal death compared with placebo.

Result

Efficacy: Kidney failure, ≥40% eGFR decline, or renal deathHR 0.82 (95% CI 0.73-0.93) · P = 0.001

Below 1 favours finerenone, above 1 favours placebo.

Event rates
Absolute difference
3.3 points
NNT
31

Absolute difference and NNT are derived from the event rates.

Original publication
Subtopic
Nonsteroidal MRA
Design
Double-blind RCT, median 2.6-year follow-up
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Bakris GL, et al. N Engl J Med. 2020;383(23):2219-2229.doi 10.1056/NEJMoa2025845

Discussion & critique

Established the nonsteroidal MRA as renoprotective; hyperkalaemia-related discontinuation 2.3% vs 0.9%.

Discussed in podcasts